MedTrace Logo

The Function of PET Molecular Imaging Targeting Fibroblast Activation Protein in the Hepatobiliary Malignancies

NCT05264688 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 80

Last updated 2022-04-27

No results posted yet for this study

Summary

Patients with high clinical suspicion of hepatobiliary malignancies should undergo PET/CT examination with two imaging agents, 68Ga-FAPI (fibroblast activation protein inhibitor) and 18F-FDG within one week, and collect tumor tissue. Finally, the PET/CT results were compared with the pathology report to evaluate the role of 68Ga-FAPI PET/CT imaging in the diagnosis of hepatobiliary malignancies

Conditions

  • Hepatobiliary Diseases

Interventions

DIAGNOSTIC_TEST

68Ga-FAPI-04 imaging agent

1.85-3.7 MBq/kg body weight (0.05-0.1 mCi/kg) intravenously

Sponsors & Collaborators

  • Zhongnan Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-20
Primary Completion
2022-07-30
Completion
2022-10-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05264688 on ClinicalTrials.gov